Securing a new credit facility with up to $100M in committed capital is a significant financial move for Zevra Therapeutics. This action not only improves the company's debt structure by refinancing existing obligations but also potentially enhances its financial stability and flexibility. Investors may view this positively as it reflects the company's ability to secure favorable financing terms, which could support future growth or operational needs. Therefore, this news is likely to have a positive short-term impact on ZVRA's stock price.